- Home
- FRD vs SRZN Comparison
FRD vs SRZN Comparison
Compare FRD & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRD | SRZN |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.2M | 164.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRD | SRZN |
|---|---|---|
| Price | $20.40 | $22.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 14.3K | ★ 149.0K |
| Earning Date | 02-06-2026 | 11-07-2025 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 43.48 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $510,450,000.00 | $3,604,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.61 | ★ N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $12.24 | $5.90 |
| 52 Week High | $23.50 | $24.94 |
Technical Indicators
Market Signals| Indicator | FRD | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 56.74 |
| Support Level | $18.25 | $19.51 |
| Resistance Level | $19.95 | $23.37 |
| Average True Range (ATR) | 0.82 | 2.12 |
| MACD | 0.17 | 0.23 |
| Stochastic Oscillator | 85.38 | 72.06 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).